Therapeutic Failure in American Cutaneous Leishmaniasis is Associated with Gelatinase Activity and Cytokine Expression

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2010 Nov 25

PMID 21091666

Citations 12

Authors

A C Maretti-Mira

M P de Oliveira-Neto

A M Da-Cruz

M P de Oliveira

N Craft

C Pirmez

Affiliations

Soon will be listed here.

Abstract

Cutaneous lesions caused by Leishmania braziliensis infection occasionally heal spontaneously, but with antimonials therapy heal rapidly in approximately 3 weeks. However, about 15% of the cases require several courses of therapy. Matrix metalloproteinase-2 (MMP-2) and MMP-9 are gelatinases that have been implicated in other chronic cutaneous diseases and skin re-epithelialization. These enzymes are controlled by their natural inhibitors [tissue inhibitors of metalloproteinase (TIMPs)] and by some cytokines. Uncontrolled gelatinase activity may result in intense tissue degradation and, consequently, poorly healing wounds. The present study correlates gelatinase activity to therapeutic failure of cutaneous leishmaniasis (CL) lesions. Our results demonstrate an association between gelatinase activity and increased numbers of cells making interferon (IFN)-γ, interleukin (IL)-10 and transforming growth factor (TGF)-β in lesions from poor responders. Conversely, high levels of MMP-2 mRNA and enhanced MMP-2 : TIMP-2 ratios were associated with a satisfactory response to antimonials treatment. Additionally, high gelatinolytic activity was found in the wound beds, necrotic areas in the dermis and within some granulomatous infiltrates. These results indicate the importance of gelatinase activity in the skin lesions caused by CL. Thus, we hypothesize that the immune response profile may be responsible for the gelatinase activity pattern and may ultimately influence the persistence or cure of CL lesions.

Citing Articles

Deciphering Host-Parasite Interplay in Infection through a One Health View of Proteomics Studies on Drug Resistance.

Tagliazucchi L, Pinetti D, Genovese F, Malpezzi G, Perea Martinez A, Manzano J ACS Infect Dis. 2024; 10(9):3202-3221.

PMID: 39088331 PMC: 11520909. DOI: 10.1021/acsinfecdis.4c00185.

Detection and activity of MMP-2 and MMP-9 in Leishmania amazonensis and Leishmania braziliensis promastigotes.

Costa B, de Queiroz Filho T, da Cruz Carneiro A, Falcao A, da Silva Kataoka M, de Jesus Viana Pinheiro J BMC Microbiol. 2023; 23(1):223.

PMID: 37587436 PMC: 10428646. DOI: 10.1186/s12866-023-02973-z.

Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?.

Leite-Silva J, Oliveira-Ribeiro C, Morgado F, Pimentel M, Lyra M, Fagundes A Microorganisms. 2023; 11(7).

PMID: 37512804 PMC: 10384164. DOI: 10.3390/microorganisms11071631.

Dual Role of Insulin-Like Growth Factor (IGF)-I in American Tegumentary Leishmaniasis.

Mendes-Aguiar C, Lopes-Siqueira C, Pettito-Assis F, Pereira-Oliveira M, de Oliveira-Neto M, Pirmez C J Immunol Res. 2021; 2021:6657785.

PMID: 33860062 PMC: 8024059. DOI: 10.1155/2021/6657785.

Insights into Molecules and Their Potential Contribution to the Virulence of the Parasite.

Elmahallawy E, Alkhaldi A Vet Sci. 2021; 8(2).

PMID: 33672776 PMC: 7924612. DOI: 10.3390/vetsci8020033.

References

Abraham M, Shapiro S, Karni A, Weiner H, Miller A . Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol. 2005; 163(1-2):157-64. DOI: 10.1016/j.jneuroim.2005.02.001. View

Fontana V, Sanchez M, Cebral E, Calvo J . Interferon-gamma inhibits metalloproteinase activity and cytotrophoblast cell migration. Am J Reprod Immunol. 2010; 64(1):20-6. DOI: 10.1111/j.1600-0897.2010.00816.x. View

Mendonca S, Coutinho S, Amendoeira R, Marzochi M, Pirmez C . Human american cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol. 1986; 64(2):269-76. PMC: 1542340. View

Agren M, Mirastschijski U, Karlsmark T . Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp Dermatol. 2001; 10(5):337-48. DOI: 10.1034/j.1600-0625.2001.100506.x. View

Makela M, Larjava H, Pirila E, Maisi P, Salo T, Sorsa T . Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp Cell Res. 1999; 251(1):67-78. DOI: 10.1006/excr.1999.4564. View

Esterre P, Dedet J, Frenay C, Chevallier M, Grimaud J . Cell populations in the lesion of human cutaneous leishmaniasis: a light microscopical, immunohistochemical and ultrastructural study. Virchows Arch A Pathol Anat Histopathol. 1992; 421(3):239-47. DOI: 10.1007/BF01611181. View

Pirmez C, Cooper C, Schubach A, Torigian V, Modlin R . Immunologic responsiveness in American cutaneous leishmaniasis lesions. J Immunol. 1990; 145(9):3100-4. View

Ridley M, RIDLEY D . Cutaneous leishmaniasis: immune complex formation and necrosis in the acute phase. Br J Exp Pathol. 1984; 65(3):327-36. PMC: 2040980. View

Coutinho S, Oliveira M, Da-Cruz A, De Luca P, Mendonca S, Bertho A . T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp Parasitol. 1996; 84(2):144-55. DOI: 10.1006/expr.1996.0100. View

10.

Woessner Jr J . The family of matrix metalloproteinases. Ann N Y Acad Sci. 1994; 732:11-21. DOI: 10.1111/j.1749-6632.1994.tb24720.x. View

11.

Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C . Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol. 2002; 197(2):179-87. DOI: 10.1002/path.1080. View

12.

Belkaid Y, Hoffmann K, Mendez S, Kamhawi S, Udey M, Wynn T . The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med. 2001; 194(10):1497-506. PMC: 2193677. DOI: 10.1084/jem.194.10.1497. View

13.

Castes M, Agnelli A, Rondon A . Mechanisms associated with immunoregulation in human American cutaneous leishmaniasis. Clin Exp Immunol. 1984; 57(2):279-86. PMC: 1536102. View

14.

Ishida Y, Kondo T, Takayasu T, Iwakura Y, Mukaida N . The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J Immunol. 2004; 172(3):1848-55. DOI: 10.4049/jimmunol.172.3.1848. View

15.

Mirastschijski U, Impola U, Jahkola T, Karlsmark T, Agren M, Saarialho-Kere U . Ectopic localization of matrix metalloproteinase-9 in chronic cutaneous wounds. Hum Pathol. 2002; 33(3):355-64. DOI: 10.1053/hupa.2002.32221. View

16.

Wysocki A, Staiano-Coico L, Grinnell F . Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993; 101(1):64-8. DOI: 10.1111/1523-1747.ep12359590. View

17.

Pirmez C, Yamamura M, Uyemura K, Conceicao-Silva F, Modlin R . Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest. 1993; 91(4):1390-5. PMC: 288111. DOI: 10.1172/JCI116341. View

18.

Harris J, Fernandez-Vilaseca M, Elkington P, Horncastle D, Graeber M, Friedland J . IFNgamma synergizes with IL-1beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis. FASEB J. 2006; 21(2):356-65. DOI: 10.1096/fj.06-6925com. View

19.

Murphy G, Willenbrock F, Crabbe T, OShea M, WARD R, Atkinson S . Regulation of matrix metalloproteinase activity. Ann N Y Acad Sci. 1994; 732:31-41. DOI: 10.1111/j.1749-6632.1994.tb24722.x. View

20.

Stearns M, Wang M, Hu Y, Garcia F, Rhim J . Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines. Clin Cancer Res. 2003; 9(3):1191-9. View